NewAmsterdam Pharma (NAMS) Research & Development (2022 - 2025)
Historic Research & Development for NewAmsterdam Pharma (NAMS) over the last 3 years, with Q3 2025 value amounting to $31.0 million.
- NewAmsterdam Pharma's Research & Development fell 1325.14% to $31.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $138.1 million, marking a year-over-year decrease of 1246.49%. This contributed to the annual value of $151.4 million for FY2024, which is 502.94% down from last year.
- According to the latest figures from Q3 2025, NewAmsterdam Pharma's Research & Development is $31.0 million, which was down 1325.14% from $27.5 million recorded in Q2 2025.
- In the past 5 years, NewAmsterdam Pharma's Research & Development registered a high of $44.8 million during Q1 2025, and its lowest value of $27.5 million during Q2 2025.
- In the last 3 years, NewAmsterdam Pharma's Research & Development had a median value of $38.4 million in 2024 and averaged $37.6 million.
- As far as peak fluctuations go, NewAmsterdam Pharma's Research & Development surged by 1175.85% in 2024, and later crashed by 2830.45% in 2025.
- Over the past 3 years, NewAmsterdam Pharma's Research & Development (Quarter) stood at $41.3 million in 2023, then fell by 15.49% to $34.9 million in 2024, then fell by 11.25% to $31.0 million in 2025.
- Its Research & Development was $31.0 million in Q3 2025, compared to $27.5 million in Q2 2025 and $44.8 million in Q1 2025.